The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from 31 May 2012 up to and including 6 June 2012 the Company bought 900 own shares representing 0.00068% of the share capital of the Company, to the total value of BGN 2066.20 on the Bulgarian Stock Exchange. The average price per share was BGN 2.296.

The shares have been bought on the basis of the general meeting resolution of 23.06.2010.

The intention of the Company is to use the repurchased shares in the future for the purpose of providing them to shareholders of companies targeted in mergers.

We would like to notify that for the month of May, 2012 Sopharma AD realized decrease of sales revenues of 2% compared with the same month of the previous year, including same level of export sales and 7% decrease of domestic sales.

During the first five months of this year Sopharma AD realized increase of sales revenues of 1%, including 13% decrease of domestic sales and 6% increase of export sales compared with the same period of 2011.

SOPHARMA AD (the “Company”) hereby informs that from 29 August 2013 up to and including 4 September 2013 the Company bought 5 250 own shares representing 0.004 % of the share capital of the Company, to the total value of 16 922 BGN on the Bulgarian Stock Exchange. The average price per share was 3.22 BGN.

The shares have been bought on the basis of decision No. 7 of the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 5 213 417, representing 3.95% of the share capital of the Company.

Sopharma AD (the “Company”) notifies that for August 2013 the Company realized a decrease of sales revenues of 8% compared to the same period of 2012, as a result of retained level of domestic sales and 12% decrease of export sales.

During the past eight months Sopharma AD recorded a decrease of sales revenues of 2%, including 4% increase of domestic sales and 5% decrease of export sales compared to the same period of 2012.

Sopharma AD (the “Company”) announces that on 10 September 2013 the Company received a notification for the acquisition of 11,885,951 shares, representing 9% of its capital, by Rompharm Company OOD. After the transaction the share of Rompharm Company OOD in the capital of Sopharma AD reached 13.53%.

Sopharma AD (the “Company”) notifies that for May 2014 the Company recorded a decrease of sales revenues of 14% compared to the same period of 2013, including same level of domestic sales and 18% decrease of export sales. The decline in export sales is mainly due to the stagnation of the Ukrainian market and the difficult access to the eastern regions of Ukraine.

During the past five months Sopharma AD recorded a decrease of sales revenues of 2%, including 2% increase of domestic sales and 3% decrease of export sales compared to 2013.

SOPHARMA AD (the “Company”) hereby informs that from 5 September 2013 up to and including 11 September 2013 the Company bought 2300 own shares representing 0.0017 % of the share capital of the Company, to the total value of 7 516.30 BGN on the Bulgarian Stock Exchange. The average price per share was 3.27 BGN.

The shares have been bought on the basis of decision No. 7 of the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 5 215 717, representing 3.95% of the share capital of the Company.

SOPHARMA AD (the “Company”) hereby informs that from 5 June 2014 up to and including 11 June 2014 the Company bought 3 000 own shares representing 0.0023% of the share capital of the Company, to the total value of 12 930 BGN on the Bulgarian Stock Exchange, the average price per share was 4.31 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 4 941 382, representing 3.74% of the share capital of the Company.

SOPHARMA AD (the “Company”) hereby informs that from 12 September 2013 up to and including 18 September 2013 the Company bought 4005 own shares representing 0.003 % of the share capital of the Company, to the total value of 13 062.13 BGN on the Bulgarian Stock Exchange. The average price per share was 3.26 BGN.

The shares have been bought on the basis of decision No. 7 of the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 5 219 722, representing 3.95% of the share capital of the Company.

The Board of Directors of Sopharma notifies that on its meeting carried out on June 16, 2014 it took a decision to initiate a procedure for merging Bulgarian Rose – Sevtopolis AD, VAT number 123007916 based in the city of Kazanlak on 110, “23d pehoten polk” Blvd. into Sopharma AD, under the regulation of the Commercial Code and art. 122 and the following of the Law on Public Offering of Securities and chooses “Elana Trading” AD VAT number 831470130 , based on 4, Kuzman Shapkarev Str. for a consultant in relation to the merger.